AL-LAD: Difference between revisions

From TripSit wiki
Jump to navigation Jump to search
No edit summary
No edit summary
 
(19 intermediate revisions by 5 users not shown)
Line 1: Line 1:
== General Information ==
[[File:allad.jpg|left|200px]]
AL-LAD, also known as 6-allyl-6-nor-lysergic acid diethylamide, is a hallucinogenic drug and an analogue of LSD. It is described by Alexander Shulgin in the book TiHKAL (Tryptamines i Have Known And Loved). While AL-LAD has subtly different effects than LSD, and appears to be slightly shorter lasting, their potencies are similar.


Check out [https://www.erowid.org/library/books_online/tihkal/tihkal01.shtml the TiHKAL entry for AL-LAD].
'''AL-LAD''' is a hallucinogenic drug, lysergamide and an analogue of [[LSD]]. It is described by Alexander Shulgin in the book ''TiHKAL'' (Tryptamines i Have Known And Loved). AL-LAD is reported as having some subtle experiential differences to LSD (such as increased visuals), and also appears to be slightly shorter lasting. AL-LAD doses are similar to those of LSD, depending on purity.
 
== History ==
 
AL-LAD was originally discovered in the 90s by David Nichols along with several LSD analogues, and later reviewed by Alexander Shulgin. The drug was popularised for recreational use in 2013, as part of the progression through the release of chemicals Shulgin discusses and provides syntheses for in his book TiHKAL. It became increasingly popular among recreational users, via the conduit of its legality and easy access through the Internet. Since then, a few countries such as the UK have moved to illegalise the chemical.


== Dosage ==  
== Dosage ==  


Common dose: 60-160 micrograms
{| class="wikitable"
|+ Oral
| Common || 60-160μg
|-
| Strong || 300μg+
|}
 
== Duration ==
 
{| class="wikitable"
|+ Oral
| Onset|| 45-90 minutes
|-
| Duration|| 4-6 hours
|}


High dose: 300 micrograms
== Effects ==


== Duration ==
In large, AL-LAD is reported as having a very similar effect profile to [[LSD]]. However, many subjective differences are noted - a different 'headspace' and slightly different visuals are noted, along with what may be perceived as a slightly 'happier' push.


Duration: 6-8 hours
== Harm Reduction ==


Come Up: 45 minutes-1.5 hours
While widespread use of AL-LAD is relatively new and therefore its full impact is unknown, it is likely that it has a similar safety profile to [[LSD]]. Refer to [[LSD]] and [[Psychedelics#Harm_Reduction|Psychedelic Harm Reduction]] for more information.


== Effects ==  
== Chemistry and Pharmacology ==
Systemaic name:6-allyl-6-nor-lysergic acid diethylamide


While AL-LAD has subtly different effects than LSD, and appears to be slightly shorter lasting.
=== Reactivity ===
AL-LAD does not cause a colour change with the marquis, mecke or mandelin reagents but does cause the ehrlich's reagent to turn purple because of the presence of the indole moiety in its structure.


== Harm Reduction ==
== Legal status ==


* Avoid driving and operating heavy machinery.
=== America ===


* Always give a few days (or even better, weeks) between psychedelic experiences.
Controlled in the United States via the Federal Analog Act, but only if it is intended for human consumption.


* Risk of exposing underlying conditions, as with any psychedelic drug.
=== United Kingdom ===


===  America ===
AL-LAD was scheduled as a Class A drug in the UK in June 2014, despite not carrying out any of the usual recommended research on proving any harm is associated with recreational use of the drug.


Controlled in the United States via the Federal Analog Act but only if it is intended for human consumption.
== Links ==
* [https://www.erowid.org/library/books_online/tihkal/tihkal01.shtml The TiHKAL entry for AL-LAD]


== User Trip Reports ==
* [https://en.wikipedia.org/wiki/AL-LAD Wikipedia]


http://nexus.tripsit.me/blog/265/300ug-al-lad-trip-report/
* [http://tripsit.me/the-story-of-al-lad The Story of AL-LAD]


[[Category:Drugs]]
[[Category:Drugs]]
[[Category:Psychedelic]]
[[Category:Psychedelic]]
[[Category:Research Chemical]]

Latest revision as of 07:04, 21 February 2016

AL-LAD is a hallucinogenic drug, lysergamide and an analogue of LSD. It is described by Alexander Shulgin in the book TiHKAL (Tryptamines i Have Known And Loved). AL-LAD is reported as having some subtle experiential differences to LSD (such as increased visuals), and also appears to be slightly shorter lasting. AL-LAD doses are similar to those of LSD, depending on purity.

History

AL-LAD was originally discovered in the 90s by David Nichols along with several LSD analogues, and later reviewed by Alexander Shulgin. The drug was popularised for recreational use in 2013, as part of the progression through the release of chemicals Shulgin discusses and provides syntheses for in his book TiHKAL. It became increasingly popular among recreational users, via the conduit of its legality and easy access through the Internet. Since then, a few countries such as the UK have moved to illegalise the chemical.

Dosage

Oral
Common 60-160μg
Strong 300μg+

Duration

Oral
Onset 45-90 minutes
Duration 4-6 hours

Effects

In large, AL-LAD is reported as having a very similar effect profile to LSD. However, many subjective differences are noted - a different 'headspace' and slightly different visuals are noted, along with what may be perceived as a slightly 'happier' push.

Harm Reduction

While widespread use of AL-LAD is relatively new and therefore its full impact is unknown, it is likely that it has a similar safety profile to LSD. Refer to LSD and Psychedelic Harm Reduction for more information.

Chemistry and Pharmacology

Systemaic name:6-allyl-6-nor-lysergic acid diethylamide

Reactivity

AL-LAD does not cause a colour change with the marquis, mecke or mandelin reagents but does cause the ehrlich's reagent to turn purple because of the presence of the indole moiety in its structure.

Legal status

America

Controlled in the United States via the Federal Analog Act, but only if it is intended for human consumption.

United Kingdom

AL-LAD was scheduled as a Class A drug in the UK in June 2014, despite not carrying out any of the usual recommended research on proving any harm is associated with recreational use of the drug.

Links